Cellectar Biosciences has closed its $103 million private placement financing, the company announced today. According to a release, the financing was led by Rosalind Advisors with participation from AIGH Capital,…
NorthStar Medical Radioisotopes has established a partnership with Curadh MTR Inc., a global molecularly targeted radiation (MTR)-focused organization, the company announced recently. According to a release, NorthStar will supply its…
NorthStar Medical Radioisotopes announced today the first patient to be treated using the radioisotope Copper-67 (Cu-67) produced from its electron accelerator. According to a release, the administration of the therapeutic…
Fifteen public and private sector organizations have formed a consortium to advance an economic development strategy aimed at bolstering Wisconsin’s lead in the biohealth industry, the organizers announced recently. According…
SHINE Technologies has demonstrated clearly visible Cherenkov radiation produced by fusion for what is believed to be the first time in history, the company announced today. “Fusion has long captured…
NorthStar Medical Radioisotopes announced today that it will provide Bayer with its environmentally preferred, non-carrier added (n.c.a.) therapeutic medical radioisotope, actinium‐225 (Ac‐225). “We are very pleased to enter this Ac-225…
Story provided by Alex Moe, WisBusiness.com. InvivoSciences, a pre-clinical stage biotech firm based in Madison, is gearing up for a potential FDA application for a heart failure drug and companion…
Exact Sciences is partnering with two renowned healthcare organizations at the forefront of cancer research, the Broad Institute of MIT and Harvard along with Baylor Scott & White, the company…
SHINE Technologies announced today it is opening the largest facility in North America dedicated to producing a medical isotope used in targeted cancer therapies. According to a release, the facility,…
Exact Sciences plans to submit next-generation Cologuard tests for FDA approval, the company announced recently. According to a release, the results from its BLUE-C study saw 94 percent sensitivity for…
